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A B S T R A C T
Objective: Palate lung nasal epithelial clone (PLUNC) is a family of proteins, which are proposed to
participate in the innate immune defense against infections in the upper aero-digestive tract. The aim of
this study was to investigate the expression of SPLUNC1 in allergic rhinitis subjects with considerations
taken to the mucosal function and smoking habits.
Methods: The participants, recruited from a cohort followed from infancy, were re-examined at the age
of 18 years regarding allergy development. Based on medical histories and skin prick tests the
participants were classiﬁed into groups with persistent allergic rhinitis (n = 18), intermittent allergic
rhinitis (n = 8) and healthy controls (n = 13). Seven subjects (3, 2 and 2 in each group, respectively)
reported smoking habits. The SPLUNC1 levels in nasal lavage ﬂuids were analyzed by Western blot.
Changes in the volume of the proper nasal cavity before and after physical exercise (Vol2increase) were
analyzed by acoustic rhinometry.
Results: Compared to the control group the SPLUNC1 level was signiﬁcantly lower in the persistent
allergy group (3.8  3.4 OD vs. 1.3  1.5 OD; p = 0.02), but not in the intermittent allergy group without
current exposure to allergens (3.6  4.7 OD). No differences were found in Vol2increase between any of the
allergy groups and controls. In smokers Vol2increase was signiﬁcantly reduced (p < 0.01) and the SPLUNC1
levels were lower compared to non-smokers. A signiﬁcant correlation was found between SPLUNC1 and
Vol2increase (p < 0.01; r = 0.53) in non-smokers.
Conclusions: Current allergen exposure has an impact on SPLUNC1 expression in nasal lavage ﬂuid, why
allergy ought to be considered in study populations where analyses of SPLUNC1 levels are included in the
reports. The normal nasal decongestion after exercise was not affected by allergy in contrast to smoking
habits. The correlation between SPLUNC1 levels and Vol2increase in non-smokers may indicate
involvement of SPLUNC1in the regulation of the normal function of the nasal mucosa. Complementary
studies are needed to conﬁrm the smoke-related reduction of SPLUNC1 expression and to analyze the
possible participation of SPLUNC1 in the nasal mucosa regulation.
 2014 The Authors. Published by Elsevier Ireland Ltd. 
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Increasing attention is being paid to a group of proteins called
palate lung and nasal epithelial clone (PLUNC), a family of related
gene products including three short proteins (SPLUNC1–3) and ﬁve
long proteins (LPLUNC1–4, 6) [1]. The SPLUNC1 protein, also
known as BPI fold-containing family A member 1 (BPIFA1) [2], is a
highly abundant secreted protein in upper airways and has been
the most studied one among the family members [3]. According toC BY-NC-SA license. 
Table 1
SPLUNC1 levels in smokers and non-smokers in the allergy and control groups. The
number of subjects with smoking habits is shown (n). Occasional (occ); moderate
(mod); optical density (OD).




PAR group 0.0  0.0 2/1/0 1.6  1.5 15
IAR group 3.0  4.3 0/1/1 3.8  5.1 6
Control group 1.9  1.2 2/0/0 4.1  3.6 11
Overall group 1.4  2.3 4/2/1 2.9  3.3 32
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localized in mucous cells and ducts of submucosal glands, but is
also found in some epithelial cells, and coats the surface epithelial
cell lining [4].
The functions of the PLUNC proteins are partly deﬁned, but new
information is continuously obtained. Great interest has been
focused on their function as a part of the innate immune defense,
which is presumed to be due to the structural homology between
the PLUNC proteins and mediators with known effects against
Gram-negative bacteria, i.e. lipopolysaccharide-binding and bac-
tericidal/permeability-increasing proteins [5,6]. The marked hy-
drophobicity and surfactant properties of the PLUNC proteins
interfere with bioﬁlm formations by airway pathogens, and these
properties are suggested to contribute to host defense [7]. The role
of antibacterial defense is supported by in vitro studies and animal
studies [8–13], as well as in human in vivo studies [14–17]. The
function and expression of PLUNC proteins have also been studied
in other upper airway disorders. In cystic ﬁbrosis [18,19] the levels
are increased. Their potential to serve as cancer biomarkers has
been evaluated [4,20–24]. Furthermore, SPLUNC1 expressions
have been analyzed in relation to exposure to airborne industrial
pollutants with known irritating effects in the airways, e.g. epoxy
chemicals [25] and carbon nanotubes. [26]. Reduced levels have
been reported in tobacco smokers [25,27].
Up to now knowledge of nasal SPLUNC1 expression in allergic
rhinitis subjects is limited. In a pilot study, including subjects with
intermittent allergic rhinitis due to pollen allergy, we previously
found reduced SPLUNC1 levels in NLF during the pollen season
compared to their levels out of season and to normal controls [28].
The aim of this report, based on results from participants in a
cohort study, was to gain further knowledge of SPLUNC1
expressions in NLF from allergic rhinitis subjects. In a previous
report based on this cohort, we found smoking habits to have an
impact on the nasal mucosal function, as the normal decongestion
after physical exercise was reduced in smokers [29]. For this reason
we found an interest to include analysis of SPLUNC1 levels in
relation to physical exercise in non-smokers and smokers in this
report.
2. Materials and methods
2.1. Subjects and allergy diagnoses
The participants were recruited from a cohort followed from
infancy to the age of 18 years regarding allergy development [30].
Diagnoses of allergy at the 18-year follow-up were based on the
histories of allergic symptoms and careful clinical examinations, all
of which were performed during winter time out of pollen season.
The participants had to be free from airway infections for at least
10 days prior to the examination. As this report is focused on
SPLUNC1 expression in NLF in relation to nasal allergy, only
subjects suffering from allergic rhinitis were included, whereas
atopic subjects with dermatitis but no airway symptoms were
excluded. Thus, allergic rhinitis with or without concurrent
bronchial or skin symptoms was diagnosed in twenty-six subjects.
2.2. Skin prick test and allergy sub-groups
The diagnosis of allergic rhinitis was veriﬁed by a skin prick test
with ALK extracts (ALK, Sweden AB) including pollen allergens
(birch, timothy, mugwort) and perennial allergens (horse, cat, dog,
D pteronyssinus, D farinae, Alternaria, Cladosporium). Based on
these results the subjects were separated into a persistent allergic
rhinitis sub-group sensitized to perennial allergens with or
without sensitization to pollens (PAR group; n = 18) and an
intermittent allergic rhinitis sub-group sensitized to pollens only(IAR group; n = 8). Healthy and prick test negative subjects served
as controls (n = 13).
2.3. Smoking habits
The subjects were asked to report active smoking habits as
occasional (1–2 cigarettes per week), low (1–9 cigarettes per day),
moderate (10–20 cigarettes per day) and heavy (>20 cigarettes per
day). A number of subjects with smoking habits are shown in
Table 1.
2.4. Symptom scores
Nasal symptoms experienced on the day of examination were
registered by the participants on visual analog scales, scoring from
0 (no symptoms) to 10 (disabling symptoms). The combined scores
of four rhinitis symptoms (itching, sneezing, secretion and
obstruction) were calculated.
2.5. Acoustic rhinometry and the physical exercise test
Exercise is known to result in an increased volume of the proper
nasal cavity due to decongestion of the nasal mucosa. This function
was evaluated by acoustic rhinometry before and immediately
after a physical exercise test (refused by two subjects in the PAR
group). The individuals had to run on a treadmill for 6 min to
achieve a pulse rate of 160 beats per minute. Acoustic rhinometry
was performed using Rhin 2000 (S.R. Electronics A.S., Lynge,
Denmark). The mean values from three recordings and the sum
from both nasal cavities were calculated using the computerized
program with pre-determined calculations of volumes and
minimal nasal cross-sectional areas [31]. The value of Vol2
corresponds to the volume in the anterior part of the proper
nasal cavity (the distance between 2.20 and 5.40 cm from the
nostrils, as calculated in Rhin 2000), and the increase after the
exercise (Vol2increase) was calculated and chosen for statistical
analysis.
2.6. Nasal lavage sampling
Nasal lavage was performed using saline pre-warmed to 37 8C.
The subject held the head bent forward with the face horizontally,
while the left nasal cavity was ﬁlled with saline, using a 10 ml
syringe connected to the nostril via a short tube and a nasal olive.
After 5 min approximately 5 ml of the saline could be recovered by
aspiration. The samples were centrifuged to remove cellular debris
and aliquots of the supernatants were stored at 20 8C in
Eppendorf tubes until analysis.
2.7. Total protein concentrations
Total protein concentrations in NLF were determined with Bio-
Rad protein assays according to Bradford [32].
Fig. 2. SPLUNC1 levels in the allergy groups and the control group. Optical density
(OD); not signiﬁcant difference (n.s.).
Fig. 1. A representative western blot image for SPLUNC1 in nasal lavage ﬂuid from
healthy controls, subjects with persistent allergic rhinitis and subjects with
intermittent allergic rhinitis. The quantiﬁcation data from the allergy group
(persistent; n = 18 and intermittent; n = 8) and healthy controls (n = 13) are shown
in Fig. 2.
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Iodoacetamide, dithiothreitol (DTT), sodium dodecyl sulfate
(SDS) and CHAPS were acquired from Sigma (Steinheim, Germany).
TEMED, Tween-20, 40% acrylamide solution, 2% bis acrylamide
solution and ammonium persulfate were purchased from Bio-Rad
(Hercules, CA, USA). Urea (pro analysis) was from Fluka (Buchs,
Switzerland), and acetonitrile and acetic acid from Riedel-de Hae¨n
(Seelze, Germany). All other chemicals were of analytical grade.
Proteins from nasal lavage ﬂuid were separated using SDS-PAGE,
with a gradient gel range T: 5–20% and C: 1.5% and a stacking gel with
T: 5% and C: 5% on Mini-Protean II electrophoresis cell from Bio-Rad
Laboratories. Samples, 0.3 mg of protein, were mixed 1:1 with
cocktail (10% (w/v) SDS, 150 mM DTT, 1% (w/v) bromophenol blue,
0.5 mM Tris–HCl pH 6.8, glycerol). As positive control nasal lavage
ﬂuid, known to contain PLUNC, was used. The samples were boiled
3 min before loaded in the wells on the SDS-PAGE and run in
electrode buffer (0.16% (w/v) Tris, 0.72% (w/v) glycine, 0.05% (w/v)
SDS). The SDS-PAGE was run for approximately 30 min in 100 V,
60 mA and then elevated to 200 V until ﬁnished.
SDS-PAGE gels were blotted on Immun-Blot PVDF Membrane
using Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad
Laboratories). Membranes were blocked in Tris-buffered saline
(40 mM Tris–HCl, 500 mM NaCl, pH 7.5) with 5% non-fat dried milk
over night. Membranes were washed with Tween-20 Tris-buffered
saline (TTBS: 40 mM Tris–HCl, 500 mM NaCl, 0.05% Tween-20) and
incubated with primary antibody against SPLUNC1 (goat polyclonal,
R&D Systems, MN, USA) in TTBS with 2% non-fat dried milk over
night. The membranes were washed with TTBS and followed by
incubation with HRP-conjugated secondary antibody (anti-goat/
sheep IgG, SIGMA, MI, USA) for 1 h. The latter wash procedure was
repeated once pursued by detection of antigen/antibody conjugate
with ECL (GE Healthcare) and developed on X-ray ﬁlm. The X-ray
ﬁlms were visualized using a cooled CCD (charged-coupled device)
camera digitizing at 1340  1040 pixels resolution (Fluor-S Multi-
Imager, Bio-Rad Laboratories, CA, USA) in combination with analysis
software Quantity One Version 4.3.1 (Bio-Rad Laboratories). The
amount of protein in a band was assessed as optical density (OD).
2.9. Statistical analyses
Statistics were analyzed by using the Graph Pad Prism software
program. The non-parametric method of Mann–Whitney U test
was used in calculations of differences between two groups.
Results are presented as mean values  1 standard deviation.
Spearman rank correlation test was used in the analyses of correlation
between two parameters. A two-tailed p-value of 0.05 was regarded
as signiﬁcant.
2.10. Ethical considerations
The study was approved by the Ethical committee at the
University Hospital in Linko¨ping, Sweden (03694). A written
informed consent was obtained from each of the participants. The
study was performed according to the principles in the Declaration
of Helsinki.
3. Results
3.1. Protein concentrations in nasal lavages
The total protein concentrations in the NLF were 250  190 mg/
ml (PAR group), 330  260 mg/ml (IAR group) and 180  100 mg/ml
(control group). No signiﬁcant statistical differences were found
between groups.3.2. Symptom scores
The combined rhinitis symptom scores were low, and the score
value of 2.8  4.1 in the PAR group was not signiﬁcantly high
compared to the values of 1.2  1.7 in the IAR group and 1.6  2.8 in
the control group.
3.3. SPLUNC1 levels in relation to allergic rhinitis
The SPLUNC1 protein could be detected by the Western blot
analysis as a distinct band at 25 kDa (Fig. 1). The mean level of
SPLUNC1, analyzed in the same amount of total protein (0.3 mg)
from each of the NLF samples, was signiﬁcantly lower in the PAR
group compared to the control group (1.3  1.5 OD vs. 3.8  3.4 OD;
p = 0.02). The mean level in IAR group (3.6  4.7 OD) was not
statistically different from the level in the control group (Fig. 2).
3.4. SPLUNC1 levels in relation to smoking habits
The smokers were equally distributed between the three
groups. The levels of SPLUNC1 were in general numerically lower
Fig. 3. The correlation between the increase of the nasal volume after exercise
(Vol2increase) and the SPLUNC1 levels in non-smokers and smokers. Optical density
(OD).
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number of smokers in the separate allergy groups was too low for
statistical calculations.
3.5. Vol2increase in relation to allergy, smoking habits and SPLUNC1
levels
In the overall group the Vol2increase was 2.1  1.4 cm3. Allergy
was not found to have any impact on this increase in contrast to
smoking habits. The level of Vol2increase was signiﬁcantly lower in the
smoking group compared to the non-smoking group (0.5  1.1 cm3;
n = 7 smokers vs. 2.4  1.3 cm3; n = 30 non-smokers; p < 0.01). A
signiﬁcant correlation was found between Vol2increase and the
SPLUNC1 levels in non-smokers (p < 0.01; r = 0.53; n = 30) (Fig. 3).
4. Discussion
This study showed that allergy has an impact on SPLUNC1
expression. The levels of SPLUNC1 were signiﬁcantly lower in the
PAR group, being currently exposed to airway allergens, as
compared to the level in the healthy control group. The SPLUNC1
level in the IAR group, being out of their pollen season with no
current allergen exposure, was not different from the controls. It is
of interest to notice, that this inﬂuence on SPLUNC1 levels is found
despite quite modest symptoms of nasal allergy with scores only
slightly and not signiﬁcantly higher in the PAR group compared to
the IAR group and the controls. The result of reduced levels of
SPLUNC1 in currently allergen exposed allergic subjects are in
accordance with the results in our previous pilot study, where
SPLUNC1 levels in NLF were analyzed by proteomic techniques
[28], showing signiﬁcantly reduced SPLUNC1 levels in pollen
allergic subjects during pollen season, but normalized values out of
season as compared to controls. Thus, two different methods of
SPLUNC1 analysis have veriﬁed signiﬁcant reductions of nasal
SPLUNC1 levels in allergic rhinitis subjects during periods of
current allergen exposure. A relation between the severity of
rhinitis symptoms and the level of SPLUNC1 would increase the
acceptance of SPLUNC1 involvement in allergic rhinitis. A relation
was supported according to the results in our previous study [28],
where the signiﬁcantly higher symptom score level during allergy
season in rhinitis subjects was associated with a signiﬁcant
reduction of the SPLUNC1 level in these subjects as compared to
healthy controls. This relation was not found in this study,
probably due to the modest levels of symptoms in the PAR subjects.
Adverse effects on the nasal mucosa due to smoke exposure
were found, even though the smoking habits were modest. The
normal exercise related increase of the nasal cavity volume wassigniﬁcantly lower in smokers compared to non-smokers; this is
previously reported [29]. Analysis of SPLUNC1 expression in
relation to smoking habits showed numerically lower levels of
SPLUNC1 in smokers compared to non-smokers in line with other
studies [25,27]. The difference did not reach statistical signiﬁcance,
probably due to the low number of participants, which were
recruited from a cohort designed for longitudinal follow-ups and
not permitting substitution of subjects excluded for various
reasons. The impact of smoking on the nasal mucosa was
expressed in a more obvious way in the analysis of SPLUNC1 in
relation to Vol2increase. These two parameters were found to
correlate signiﬁcantly, but only in non-smoking individuals. This
relation was not detected in smokers, apparently due to the
reduction of SPLUNC1 levels as well as of the Vol2increase values.
The association between SPLUNC1 and the normal decongestion of
the nasal mucosa has to our knowledge not been described
previously and further studies are needed in order to explain the
mechanisms behind the results. We can only speculate on the
implication of this correlation, whether it is an indication of a
participation of SPLUNC1 in the normal function of the nasal
mucosa, or whether the elasticity of the mucous membrane as well
as the level of SPLUNC1 is affected in parallel by some common
factor. Such a factor might be neutrophil elastase, which is
described to reduce SPLUNC1 [33].
In conclusion, our analyses of SPLUNC1 expressions in NLF have
shown new and valuable information. Current allergen exposure,
even at low levels causing modest clinical symptoms, has a
signiﬁcant impact on SPLUNC1 levels in allergic rhinitis subjects.
Thus, it could be of importance, even in non-allergic upper airway
disorders, to consider current respiratory allergy in study
populations, where nasal SPLUNC1 levels are compared inter-
individually. However, SPLUNC1 cannot be regarded as an
adequate biomarker of allergy in single subjects, due to over-
lapping values between allergic and healthy individuals.
Smoking habits were found to have adverse effects on the
SPLUNC1 levels and mucosal function. The possible involvement of
SPLUNC1 in the normal function of the nasal mucosa, indicated by
the signiﬁcant correlation in non-smokers between SPLUNC1
levels and the increase in nasal volumes, needs further analyses
including the way it is impaired by tobacco smoke.
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